Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 6,936 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control, small Clear all

Conditions: Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion, Stage IV Non-small Cell Lung Cancer
Interventions: Tamibarotene, Placebo; Drug
Lead sponsor: CytRx; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Rancho Mirage, California • Kansas City, Kansas • Hackensack, New Jersey

Conditions: Pain
Interventions: Thermal Sensory Analyzer, Pressure Stimuli, Mechanical Stimuli, Pain Ratings, Thermal pain thresholds, Pressure pain thresholds (PPT), Mechanical temporal summation, Conditioned pain modulation (CPM) efficiency, Offset analgesia efficiency, Cold pain tolerance; Device · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 9 Years to 16 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity
Interventions: Mindful eating and movement; Behavioral
Lead sponsor: Northeastern University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stage 4 NSCLC
Interventions: Pfizer-BioNTech mRNA COVID-19 vaccine; Biological
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Type1 Diabetes Mellitus
Interventions: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, iLet Bionic Pancreas insulin-only configuration with Fiasp, Usual care; Device · Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Palo Alto, California • Aurora, Colorado • Jacksonville, Florida

Conditions: Physical Activity
Interventions: Faith-based, Non-faith-based; Behavioral
Lead sponsor: Melicia Whitt-Glover; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 496 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cancer
Interventions: protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy; Genetic · Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 120 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Flank Mass
Interventions: RZL-012, Placebo; Drug
Lead sponsor: Raziel Therapeutics Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Substance Use, Substance Abuse, Suicide
Interventions: Thiwáhe Gluwáš'akapi, Woyute Waśte; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 85 Years
Enrollment: 552 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Pevonedistat, Venetoclax, Azacitidine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 23
States / cities: Gilbert, Arizona • La Jolla, California • Orange, California + 20 more

Conditions: Pain
Interventions: Fentanyl; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metatarsal Fracture
Interventions: AccelStim (LIPUS); Device
Lead sponsor: Orthofix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Evanston, Illinois • Mount Prospect, Illinois • Laurel, Maryland

Conditions: Chronic Insomnia
Interventions: Expert Recommendations for Implementing Change bundle of strategies, Brief Behavioral Treatment for Insomnia; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 277,920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Stroke, Acute
Interventions: Harmony SHR, Traditional Occupational Therapy; Device · Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 21 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 26
States / cities: Scottsdale, Arizona • Los Angeles, California • Orange, California + 23 more

Conditions: Biliary Atresia
Interventions: Odevixibat, Placebo; Drug
Lead sponsor: Albireo, an Ipsen Company; Industry
Eligibility: Up to 111 Days
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 30
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 25 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Gemcitabine, LY293111, cisplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 6
States / cities: Birmingham, Alabama • Boston, Massachusetts • Manhasset, New York + 3 more

Conditions: Cardiac Amyloidosis
Interventions: • Cardiac Rehabilitation; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Emotion Regulation
Interventions: Reflective Supervision Enhancement; Behavioral
Lead sponsor: Bradley Hospital; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Riverside, Rhode Island

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Docetaxel, Gemcitabine, Lurbinectedin (PM01183); Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Erectile Dysfunction
Interventions: sildenafil, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 31
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Beverly Hills, California + 26 more

Conditions: Anterior Shoulder Dislocation, Recurrent Shoulder Dislocation, Shoulder Subluxation, Surgery
Interventions: Blood flow restriction therapy, Standard Physical Thearapy; Other
Lead sponsor: Keller Army Community Hospital; Federal
Eligibility: 17 Years to 30 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: West Point, New York

Conditions: Stroke
Interventions: The Stride Management Assist (SMA) System, Impairment based therapy; Device · Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 85 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Essential Tremor
Interventions: Limb Cooling Assessment of ET; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 95 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Pain Sensitivity During Puberty

The Mind-Body Project

Universal Immunization to Fortify Immunotherapy Efficacy and Response

The Insulin-Only Bionic Pancreas Bridging Study

A Program to Increase Physical Activity Among Blacks

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks

Evaluation of Thiwáhe Gluwáš'Akapi Substance Use Prevention Program

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

Safety Study of Analgesia After Craniotomy Surgery With End Tidal (ET) Carbon Dioxide (CO2) Monitoring

A Data Collection Protocol to Evaluate the Real World Usage of the Orthofix AccelStim Device to Treat Fresh Metatarsal Fractures

Enhancing Access to Insomnia (EASI) Care in VA PCMHI Clinics

Harmony Scapulohumeral Rhythm (SHR) Reliability and Efficacy Study

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study

Enhancing Early Care and Education Through Reflective Supervision

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate

Blood Flow Restriction Training Versus Standard Physical Therapy After Shoulder Stabilization Surgery

Development of Walk Assist Device to Improve Community Ambulation

Limb Cooling in Essential Tremor